| Value | ₹1.21 Cr |
|---|---|
| Execution period | Expected to close by 15th May, 2026 |
NSE filing, NSE: SATKARTAR. Summary written from the filing by ALFA Finder's alert engine.
Sat Kartar Life Ltd: key numbers
- Share price
- ₹130.00
- Market cap
- ₹205.3 Cr
- Revenue (annual)
- ₹200.7 Cr
- Net profit (annual)
- ₹17.10 Cr
- P/E (TTM)
- 12.0×Sector 45.9×
- Promoter holding
- 63.49%
- FII holding
- 0.77%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sat Kartar Life Ltd
All →Sat Kartar Life Capacity Expansion: ₹1 Cr Investment
Sat Kartar Life proposes a 25-bed Ayurveda hospital-cum-therapy centre in Lucknow at ₹1 Crore investment. Expected operational by February 2027 as part of its healthcare network expansion.
- Value
- ₹1.00 Cr
- Execution
- Expected operational by February 2027
- hospital beds
- 25 beds
Sat Kartar Life Earnings Call Transcript: Key Takeaways
Sat Kartar Life is pivoting from pure Ayurveda products to an integrated healthcare model, showing strong revenue growth but scaling back prior top-line guidance to prioritize margins.
- Call
- Guides 32% growth
Sat Kartar Life H1 FY27 Results: Net Profit ₹9.2 Cr, Up 26.0% YoY
Sat Kartar Life Ltd reported revenue from operations of ₹113.9 Cr (+26.4% YoY) and net profit of ₹9.2 Cr (+26.0% YoY) for H1 FY27.
- Key figure
- Net profit ₹9.2 Cr · +26.0% YoY
Sat Kartar Life Investor Presentation: Key Takeaways
H1 FY27 deck discloses no revenue, PAT or EBITDA figures. Balance sheet is debt-free with ₹18.7 Cr net cash. Growth is hospital-led: 30-bed Delhi unit at breakeven, 300 beds targeted by FY27-end.
Sat Kartar Life Results Update
Sat Kartar Life Limited reported H1 FY27 revenue growth of 26% and EBITDA growth of 48% via press release. Its first Ayurveda hospital reached operating breakeven.
Sat Kartar Life Other Announcement
Sat Kartar Life filed CARE Ratings' IPO proceeds monitoring report for half year ended September 2026. It shows nil deviation from objects, so no new event occurred.
Other acquisition announcements
All →Bondada Engineering Acquisition Worth ₹2.5 Cr
Subsidiary Atpole Technologies bought 5,100 shares of electric two-wheeler maker BTM Mobility for Rs 2.50 Crore cash. The completed deal targets inorganic growth in e-two-wheelers.
- Value
- ₹2.50 Cr
Kalpataru Acquisition Worth ₹0.49 Cr
Kalpataru's step-down subsidiary, Kalpataru Properties, is acquiring 16.67% equity in Agile Real Estate Dev for Rs 0.49 Crore in cash. The stake purchase will make the target a step-down wholly owned subsidiary.
- Value
- ₹0.49 Cr
- Execution
- Within 60 days, subject to requisite approvals
Bondada Engineering Acquisition
Bondada Engineering's subsidiary ATPL acquired 51% of BTM Mobility Pvt Ltd, an electric two-wheeler manufacturer. The acquisition is for cash consideration; no specific amount was disclosed.
Kalpataru Acquisition Worth ₹52.55 Cr
Kalpataru's subsidiary KPL approved acquiring 16.67% of step-down subsidiaries AREPL and AREDPL for ₹52.55 Crore. This makes them wholly owned, giving Kalpataru 100% of Kalpataru Parkcity project cash flows at Thane.
- Value
- ₹52.55 Cr
- Execution
- 60 days, subject to receipt of requisite approvals
Zydus Lifesciences Acquisition Worth ₹84 Cr
Zydus Lifesciences acquired Sterling Biotech's API business for Rs. 84 Crore via slump sale. The deal covers fermentation-based API products and is completed.
- Value
- ₹84.00 Cr
Zydus Lifesciences Acquisition Worth ₹167 Cr
Zydus Lifesciences completed acquisition of Sterling Biotech's API business for Rs. 167 Crore. The slump sale of fermentation-based API products strengthens its manufacturing portfolio.
- Value
- ₹167.0 Cr